Your browser doesn't support javascript.
Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.
Tantry, Udaya S; Schror, Karsten; Navarese, Eliano Pio; Jeong, Young-Hoon; Kubica, Jacek; Bliden, Kevin P; Gurbel, Paul A.
  • Tantry US; Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD, USA.
  • Schror K; Department of Pharmacology and Clinical Pharmacology, Heinrich-Heine-University, Düsseldorf, Germany.
  • Navarese EP; Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Jeong YH; Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea.
  • Kubica J; Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Bliden KP; Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD, USA.
  • Gurbel PA; Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, LifeBridge Health, Baltimore, MD, USA.
J Exp Pharmacol ; 13: 957-970, 2021.
Article in English | MEDLINE | ID: covidwho-1575723
ABSTRACT

INTRODUCTION:

Pharmacologic therapy options for COVID-19 should include antiviral, anti-inflammatory, and anticoagulant agents. With the limited effectiveness, currently available virus-directed therapies may have a substantial impact on global health due to continued reports of mutant variants affecting repeated waves of COVID-19 around the world.

METHODS:

We searched articles pertaining to aspirin, COVID-19, acute lung injury and pharmacology in PubMed and provide a comprehensive appraisal of potential use of aspirin in the management of patients with COVID-19. The scope of this article is to provide an overview of the rationale and currently available clinical evidence that supports aspirin as an effective therapeutic option in COVID-19.

RESULTS:

Experimental and clinical evidence are available for the potential use of aspirin in patients with COVID-19.

DISCUSSION:

Aspirin targets the intracellular signaling pathway that is essential for viral replication, and resultant inflammatory responses, hypercoagulability, and platelet activation. With these multiple benefits, aspirin can be a credible adjunctive therapeutic option for the treatment of COVID-19. In addition, inhaled formulation with its rapid effects may enhance direct delivery to the lung, which is the key organ damaged in COVID-19 during the critical initial course of the disease, whereas the 150-325 mg/day can be used for long-term treatment to prevent thrombotic event occurrences. Being economical and widely available, aspirin can be exploited globally, particularly in underserved communities and remote areas of the world to combat the ongoing COVID-19 pandemic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews Topics: Variants Language: English Journal: J Exp Pharmacol Year: 2021 Document Type: Article Affiliation country: JEP.S330776

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Reviews Topics: Variants Language: English Journal: J Exp Pharmacol Year: 2021 Document Type: Article Affiliation country: JEP.S330776